Naoki Kanomata

13PUBLICATIONS
12CO-AUTHORS
Solid tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Clinical midwiferyMolecular imaging (incl. electron microscopy and neutron diffraction)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 13, 2026
Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass.

|May 14, 2026
Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery.

|Mar 02, 2026
Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.

Masayuki Sano, Masaki Shimbo, Shin Ohgita

|May 13, 2025
Reevaluating HER2-null breast cancer using an enhanced HER2 immunohistochemistry protocol.

Takeshi Ushigusa, Nami Hirakawa, Naoki Kanomata

|Apr 13, 2025
Reply to the letter to the editor "Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients".

Takeshi Ushigusa, Atsushi Yoshida, Naoki Kanomata

|Mar 17, 2025
Correction: Clinicopathological significance of androgen receptor expression and tumor infiltrating lymphocytes in triple-negative breast cancer: a retrospective cohort study.

Takeshi Ushigusa, Nami Hirakawa, Yuka Kajiura

Pageof 3

Frequent Collaborators

4 joint publications

Takeshi Ushigusa

4 joint publications

Atsushi Yoshida

1 joint publications

Nami Hirakawa

1 joint publications

Masayuki Sano